Compare Hershey Co (HSY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Vertex Pharmaceuticals Incorporated — how do they compare? Hershey Co trades at $180.3 (market cap $36.56B), while Vertex Pharmaceuticals Incorporated trades at $527.4 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.7× Hershey Co's market cap, and Hershey Co pays a 3.19% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| HSY | VRTX | |
|---|---|---|
Market Cap | $36.56B | $134.25B |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $529.65 |
52-Week Low | $162.31 | $376.62 |
Enterprise Value | $41.70B | $128.37B |
Dividend Yield | 3.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $182.75, up 0.22% with a bullish technical signal and strong fundamental momentum. The stock shows consistent earnings beats with Q2 2026 EPS of $1.90 exceeding expectations by 33%, while revenue growth trends upward to $11.69 billion in 2025. Analyst consensus targets $196.78 with 69% hold ratings, reflecting cautious optimism amid margin recovery from favorable cocoa contracts and dividend growth.
The outlook remains positive with earnings rebound and pricing power, though risks include volume declines and competitive pressures. Current valuation at 24.86 P/E appears reasonable given 32.81% ROE and improving cash flow trends. Institutional sentiment is mixed with recent insider sales offset by upward guidance revisions.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
